Senior Principal Scientist at Bristol Myers Squibb, Apply Now!
Looking to make a real impact in translational medicine and biomarker development? Bristol Myers Squibb is hiring a Senior Principal Scientist to lead biomarker strategies and CDx development in its China R&D portfolio. This role offers the opportunity to drive cross-functional collaboration, support clinical trials, and represent the company in health authority interactions—all while advancing science that transforms lives.
Job Title: Senior Principal Scientist
Duties/Responsibilities:
- Responsible for biomarker related activities in assigned clinical studies or programs in China R&D portfolio.
- Drive global and cross-functional team work to develop China biomarker assessment and CDx development strategy aligned with the global strategy.
- Identify scientific gaps or a specific tailored biomarker strategy relevant for China for a certain asset.
- Drive and monitor activities of biomarker assessment and CDx development alongside with clinical trials to support China clinical development strategy.
- Serve as a local representative for health authority interactions, responsible for elements relevant to translational medicine and biomarkers.
- Contribute to local KOL engagement meetings with scientific knowledge and leadership in translational medicine.
Experience Requirements:
- PhD in life sciences or relevant areas with strong scientific capabilities demonstrated by track-record publications.
- Pharmaceutical industry experience of at least 5 years.
- Strong communication skills for cross-functional team engagement.
Key Competency Requirements:
- Leading Compliance & Integrity Culture.
- Leading Self.
Education/Experience/Licenses/Certifications:
PhD in Life Sciences or relevant areas
Travel Required: This position requires up to 10% of travel
If you are excited about this role and are ready to contribute your expertise, we encourage you to apply. Transform your career with Bristol Myers Squibb!
Keywords: Senior Principal Scientist, Bristol Myers Squibb, biomarker, clinical trials, China R&D portfolio, pharmaceutical industry, translational medicine
